Regulatory Affairs Head

Persona 04 / 04

— A scene from submission preparation

The regulatory affairs lead writing toward a filing.

Has read every recent CRL in their indication, but not at a level of detail that lets them write the deficiency-anticipating cover letter they want to write. Wants to know what FDA is actually citing — endpoint adequacy, statistical analysis plan, CMC stability, patient population — and how the recent submission strategies in the indication actually mapped to the questions FDA asked at advisory committee.

“

What deficiencies has FDA cited on similar submissions? Where do our competitors' cover letters tell us they expected pushback?

— a question we hear from regulatory leads four to nine months pre-submission

What Brioche delivers

A precedent-grounded submission intelligence brief. A structured read of every recent CRL, complete-response action, and advisory-committee transcript in the indication, organized by deficiency type and mapped against the strategies sponsors used to recover or fail.

CRL pattern analysis Every CRL in the indication for a defined window, normalized against deficiency category — endpoint, SAP, CMC, label, patient population, post-marketing. Recovery paths attributed where public.
AdCom intelligence Voting records, panelist commentary, FDA briefing document language, and sponsor response packages — read for the questions that get asked and the answers that work.
Submission strategy How comparable programs structured their Module 2 summaries, what they led with, what they buried, and what FDA pushed back on. Tone, sequence, and emphasis.
Format A written intelligence report. A working session with regulatory and clinical. Direct access during the back half of submission preparation.

Illustrative scenario · not a real engagement Scenario sketch

Preparing an NDA in a narrow indication where two recent submissions received complete-response letters citing endpoint adequacy and post-hoc subgroup analysis.

The regulatory lead wants to write the SAP — and the cover letter — with a clear-eyed read of which deficiencies recurred, which sponsors recovered, and how. The pattern is in the public record; reading it cleanly is a question of completeness, not access.

— Track 01

Deficiency pattern. Parse every CRL in the indication for the past five years against the structured deficiency taxonomy. Surface the recurring categories. Quote FDA's actual language.

— Track 02

Recovery posture. For each CRL, trace whether the sponsor resubmitted, what they changed, and whether the second action was approval, second CRL, or withdrawal. Attribute the strategic difference where public.

— Track 03

Submission posture. Read your competitive set's Module 2 summaries and AdCom briefing books for what they led with, what they conceded, and what FDA still asked. Inform the cover letter and the SAP, not the entire dossier.

The regulatory affairs lead writing toward a filing.

What Brioche delivers

Preparing an NDA in a narrow indication where two recent submissions received complete-response letters citing endpoint adequacy and post-hoc subgroup analysis.

How other teams use Brioche.